May 4, 2019
Edition 12
The FDA granted accelerated approval to Atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab) Paclitaxel (Abraxane) for unresectable locally advanced…
April 29, 2019
Edition 11
In a recent clinical trial, researchers have found promising clinical activity of Pembrolizumab with Trastuzumab in patients with PD-L1 positive,…
April 29, 2019
Edition 10
In a recent clinical trial, researchers found that patients with a higher tumor mutational burden, T cell inflamed gene expression profile and PDL-1 expression…
April 29, 2019
Edition 09
The FDA approved Osimertinib (Tagrisso) for the first-line treatment of metastatic NSCLC with (EGFR) exon 19 deletions or exon 21 L858R mutations (Read More).…
April 29, 2019
Edition 08
The FDA granted approval to Gilteritinib for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation…
April 29, 2019
Edition 07
A prospective cohort study of 323 patients with metastatic NSCLC showed marked increase in detection of therapeutically targetable mutations and improved…
April 29, 2019
Edition 06
The targeted therapy Venetoclax (Venclexta) can now be used for a broader group of patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug…
September 14, 2018
Edition 05
The targeted therapy Venetoclax (Venclexta) can now be used for a broader group of patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug…
August 2, 2018
Edition 04
The US Food and Drug Administration (FDA) has approved Pembrolizumab (Keytruda) for patients with recurrent or metastatic cervical cancer with disease…
- 1
- 2
“So much to read, so little time!”
Does that sound familiar to you?
Being abreast of the latest developments – in science and in clinical practice can be of tremendous help – if only you had enough time to read.
We would like to help.
COREssence brings you a collection of scientific developments in in form of small, bite-size summaries.